Abemaciclib is a potent and selective inhibitor of CDK 4 and 6, approved for treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer, as monotherapy or with endocrine therapy. Here, ERBB2 is linked to breast carcinoma.